Anti-cancer High Jewelry

Like a master jeweler who meticulously sets each stone to enhance the brilliance of a jewel, our project leader is crafting a new generation of ADCs—targeted anticancer therapies designed to eliminate cancer cells while preserving healthy ones.

 The technology under development will refine and secure the attachment of toxins to the guided missile (antibody), making these targeted therapies less toxic, more effective, and opening the door to further innovations. Initially applied to particularly hard-to-treat breast cancers, it will later be extended to many other types of cancer.

Within the anticancer arsenal, there are targeted therapies—called ADCs—that use “guided missiles” to deliver highly potent toxins directly to cancer cells in order to destroy them.

However, these therapeutic jewels still face certain setting flaws.
If the toxins are not properly attached to the missile, they may detach before reaching their target and damage healthy cells.

The solution developed by our project leader is based on an ultra-precise ADC manufacturing method that firmly anchors the toxins to the missile.
The precious stones are perfectly set to reveal the full beauty and power of the jewel.

 Advantage #1: Reduced toxicity
The toxins remain attached to the missile throughout their journey in the body. By not being lost along the way, they avoid damaging healthy cells.

Advantage #2: Greater efficacy
With this secure delivery system, higher doses can be used to increase the treatment’s effectiveness against targeted cancer cells.

Advantage #3: Greater innovation
Thanks to these improvements, entirely new designs can be envisioned, combining several complementary toxins on a single missile.

To date, ADCs are already regularly used in the treatment of various cancers (certain breast cancers, bladder cancer, lung cancer, ovarian cancer).

The technology developed by our project leader will first be applied to certain particularly difficult-to-treat breast cancers, with strong potential for expansion to many other types of cancer.

By improving the safety of ADCs, we will strengthen their clinical value and broaden the range of treatable cancers.